Trials Sponsors Conditions Drugs Pricing

Conditions

Amyloid Cardiomyopathy Chemotherapy Effect Congestive Heart Failure

Keywords

Cardiac amyloidosisCardiomyopathyHeart failureChemotherapyEchocardiographyStrain imaging

Outcome Measures

Primary Outcomes (1)

The longitudinal changes in left and right ventricular global strain after chemotherapy in cardiac light chain amyloidosis
In this study, the effects of treatment strategies on left and right ventricular global and regional strain and its relationship with mortality and morbidity will be investigated in patients with AL-amyloidosis, who are still under treatment, and newly diagnosed with AL-amyloidosis.
Change from Baseline left and right ventricular global strain at 1 year

Secondary Outcomes (1)

Evaluation of the effects of treatment strategies on other cardiac morphological and functional changes in standard echocardiographic imaging
Baseline, and 1st, 3rd, 6th, 12th Month follow-up

Study Arms (1)

Light Chain Cardiac Amyloidosis

Participants with light chain cardiac amyloidosis actively receiving chemotherapy or undergoing autologous bone marrow transplant

Diagnostic Test: Left and Right Ventricular Global Strain Imaging

Interventions

Left and Right Ventricular Global Strain ImagingDiagnostic test

Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.

Also known as: TomTec AutoStrain Suite Software, Philips Epiq CVx Echocardiography System, Philips X5-1 3D Echocardiography Probe

Light Chain Cardiac Amyloidosis

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients aged 18-90 years with cardiac primary light chain amyloidosis or due to multiple myeloma who are newly diagnosed, currently receiving chemotherapeutic treatment, or are scheduled for bone marrow transplantation will be recruited.

You may qualify if:

≥18 years old

Sponsors & Collaborators

Istanbul University - Cerrahpasa
Otherlead

Study Sites (1)

Istanbul University-Cerrahpasa

Istanbul, Fatih, 34098, Turkey (Türkiye)

Related Publications (3)

Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, Hanna M. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. J Am Coll Cardiol. 2016 Jun 28;67(25):2941-8. doi: 10.1016/j.jacc.2016.03.593.
PMID: 27339491RESULT
Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019 Sep 24;1(1):117-130. doi: 10.1016/j.jaccao.2019.08.002. eCollection 2019 Sep.
PMID: 34396169RESULT

MeSH Terms

Conditions

Amyloid Neuropathies, FamilialHeart FailureCardiomyopathies

Condition Hierarchy (Ancestors)

Heredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesNervous System DiseasesAmyloid NeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAmyloidosis, FamilialMetabolism, Inborn ErrorsMetabolic Diseases

Study Officials

Burçak Kılıçkıran Avcı, Assoc Prof.
Istanbul University - Cerrahpasa
STUDY CHAIR
Deniz Mutlu, MD
Istanbul University - Cerrahpasa
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

July 2, 2022

First Posted

July 11, 2022

Study Start

August 11, 2022

Actual (reported)

Primary Completion

September 26, 2023

Actual (reported)

Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Light Chain Cardiac Amyloidosis

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Light Chain Cardiac Amyloidosis

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations